Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients
- 1 January 2016
- journal article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 174 (1) , 17-24
Abstract
Context and objective The role of cabergoline in Cushing's disease (CD) remains controversial. The experience is limited to case reports and few open studies that report the effects determined after ≥1 month of treatment. In prolactinomas and dopamine-responsive GH-secreting tumours, effects of cabergoline are seen within days or weeks. Here, we searched for short-term effects of cabergoline in CD. Design Twenty patients (19 naïve and one recurrent) were included in a prospective study. Cabergoline was administered in increasing doses of 0.5–5 mg/week over 6 weeks. Methods Urinary free cortisol (UFC) 24 h, morning cortisol and ACTH, and salivary cortisol at 0800, 1600 and 2300 h were determined once weekly throughout. Diurnal curves (six samples) of serum cortisol were measured at start and end. Results At study end, the median cabergoline dose was 5 mg, range 2.5–5 mg/week. The prolactin levels, markers of compliance, were suppressed in all patients. During the treatment, hypercortisolism varied, gradual and dose-dependent reductions were not seen. Five patients had a >50% decrease of UFC, three had a >50% rise of UFC. Salivary cortisol at 2300 h showed a congruent >50% change with UFC in two of the five cases with decreased UFC, and in one of the three cases with increased UFC. One patient with decreases in both UFC and 2300 h salivary cortisol also had a reduction in diurnal serum cortisol during the course of the study. Conclusions Cabergoline seems to be of little value in the management of CD. Only one patient had a response-like pattern. Given the known variability of disease activity in CD, this might represent a chance finding.Keywords
This publication has 29 references indexed in Scilit:
- High Prevalence of Normal Tests Assessing Hypercortisolism in Subjects with Mild and Episodic Cushing's Syndrome Suggests that the Paradigm for Diagnosis and Exclusion of Cushing's Syndrome Requires Multiple TestingHormone and Metabolic Research, 2010
- Treatment of Adrenocorticotropin-Dependent Cushing’s Syndrome: A Consensus StatementThe Journal of Clinical Endocrinology & Metabolism, 2008
- The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2008
- Cyclic Cushing’s syndrome: a clinical challengeEuropean Journal of Endocrinology, 2007
- Nelson’s Syndrome: Complete Remission with Cabergoline but Not with Bromocriptine or Cyproheptadine TreatmentHormone Research in Paediatrics, 2004
- Dopamine as a Prolactin (PRL) InhibitorEndocrine Reviews, 2001
- Effect of injectable bromocriptine in patients with Cushing's diseaseExperimental and Clinical Endocrinology & Diabetes, 1995
- LONG‐LASTING LOWERING OF SERUM GROWTH HORMONE AND PROLACTIN LEVELS BY SINGLE AND REPETITIVE CABERGOLINE ADMINISTRATION IN DOPAMINE‐RESPONSIVE ACROMEGALIC PATIENTSClinical Endocrinology, 1988
- RESPONSE TO NEUROTRANSMITTER MODULATING DRUGS IN PATIENTS WITH CUSHING'S DISEASEClinical Endocrinology, 1986
- EFFECT OF BROMOCRIPTINE IN PITUITARY‐DEPENDENT CUSHING'S SYNDROMEClinical Endocrinology, 1983